Balchem Corp (BCPC)

Balchem Corp. has demonstrated robust financial performance, reporting strong fourth-quarter and full-year 2025 financial results with record net sales, adjusted EBITDA, and free cash flow. Net sales for the fourth quarter of 2025 increased by 9.8% to $263.6 million, and full-year 2025 net sales reached a record $1.037 billion, an 8.8% increase over the prior year. Balchem has also consistently rewarded shareholders, increasing its dividend for the 17th consecutive year. The stock has seen a 17.14% increase over the last year, and analysts have a "Buy" consensus rating for BCPC. The stock's price as of April 2, 2026, was $170.42 per share, representing a 9.40% increase from April 4, 2025.

Balchem generally experiences healthy demand across the vast majority of its end markets. The Human Nutrition and Health segment sees strong demand driven by consumer shifts towards "better-for-you" foods. The Animal Nutrition and Health segment also sees healthy demand, particularly with a recovery in dairy markets, and experiences some seasonality. The Specialty Products segment, particularly Performance Gases, has experienced strong performance and healthy demand, while Plant Nutrition experiences seasonality tied to agricultural growing seasons.

Balchem Corp. is a global specialty ingredients company operating in the Specialty Chemicals sector. It develops, manufactures, and markets performance ingredients and products across various high-growth markets. The company's business is segmented into Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides nutrients, mineral amino acid chelated products, specialty vitamin K2, MSM, and customized food and beverage ingredient systems. The ANH segment focuses on nutritional products to enhance the health and productivity of animals. The Specialty Products segment is involved in the repackaging and global distribution of performance gases and provides foliar-applied chelated minerals and specialty micronutrients to the agricultural market.

Balchem Corporation's corporate headquarters is located in Montvale, New Jersey, USA. The company has a broad network of 22 manufacturing sites and 8 R&D technology centers globally, primarily situated in the U.S. and Europe. Its manufacturing facilities are located in various U.S. states including Minnesota, Missouri, Louisiana, Nebraska, New York, Ohio, South Carolina, Utah, Virginia, and Wisconsin, as well as internationally in Alberta, Canada, and multiple locations in Italy, Belgium, and Norway. Regional offices are present in the Netherlands, Belgium, Germany, Norway, and several U.S. cities. Balchem has an expanding international reach and a robust presence in North America.

Balchem has built a strong reputation for its dedication to quality, safety, and sustainability, and for delivering results to all its stakeholders. The company emphasizes its commitment to enhancing the health and well-being of people and animals through innovative, science-backed specialty ingredients. Sustainability is a key pillar of Balchem's vision, with a focus on ESG topics and a commitment to reducing Scope 1 and Scope 2 greenhouse gas emissions and water usage by 25% from a 2020 baseline by 2030. Balchem's reputation has been positively reinforced by its strong financial performance and continued innovation.

Balchem Corp. is predominantly owned by institutional shareholders, who hold approximately 89.53% of the stock. Retail investors own about 8.02%, and Balchem insiders hold 2.45%. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and State Street Corp. Other significant institutional shareholders include Conestoga Capital Advisors, LLC, Wasatch Advisors Inc, Geode Capital Management, Llc, Morgan Stanley, Dimensional Fund Advisors Lp, Fmr Llc, and Jpmorgan Chase & Co.